AI-Powered | Label-Free | High-Res Imaging & Sorting | Drug Discovery
Understanding how cells respond to therapeutics is critical for developing effective treatments. Traditional assays often miss subtle or heterogeneous phenotypes that can reveal how a drug works or why resistance emerges.
In this webinar, Dr. Hani Goodarzi (Arc Institute, UCSF) will share how high-dimensional morphology analysis and deep learning can be used to study drug response and uncover mechanisms of action (MoA) at single-cell resolution. By combining Deepcell’s platform with artificial intelligence (AI), his team is mapping morphological phenotypes and identifying novel MoA signatures.
Join us for an in-depth look at how AI-powered morphology profiling decodes cellular responses and accelerates therapeutic discovery.
Why Attend?
- Gain exclusive insights from a leading expert in drug response mechanisms, working at the intersection of machine learning and cancer biology.
- Learn how Deepcell’s technology is revolutionizing drug discovery with AI-powered, label-free morphology profiling.
- Engage in a live Q&A session with Dr. Goodarzi and Deepcell's CEO & Co-founder, Maddison Masaeli.
What You'll Learn
- High-dimensional, morphology-based profiling for drug discovery
- AI/ML enables unbiased MoA analysis of drug response label-free
- Novel morpholomics method to complement downstream analysis such as proteomics, transcriptomics, and genomics.
Meet the Speaker
Dr. Hani Goodarzi is an Arc Institute Core Investigator and Associate Professor at UCSF. His research combines novel discovery platforms and frontier AI models to reveal molecular mechanisms of cancer progression. Dr. Goodarzi has made key scientific contributions at the intersection of AI, RNA biology, and cancer research, and in both diagnostics and therapeutics. He has also co-founded several companies in this field, including Exai Bio, a next-generation liquid biopsy company, and Vevo Tx, a platform drug discovery leveraging AI to design better drugs. His work has been recognized with prestigious awards, including the Vilcek Prize for Creative Promise and the AACR-MPM Transformative Cancer Research Award.
Live Q&A
About Deepcell
Deepcell is a life science company which brings artificial intelligence to cell biology, unlocking a new field of high-dimensional biological discovery known as morpholomics. Through Deepcell’s AI-powered imaging and microfluidics solution, the REM-I Platform, the company is enabling a new scale of cell biology research and single cell analysis leveraging cellular morphology for unbounded discovery. Deepcell’s platform leverages its artificial intelligence model, the Human Foundation Model, to identify and sort cells based on morphological distinctions helping power basic and translational research and offering future applications in diagnostic testing and therapeutics targeting. The company was spun out of Stanford University in 2017 and has raised nearly $100 million in venture capital. It is based in Menlo Park, California. Learn more at www.deepcell.com or follow us on LinkedIn, Twitter, and YouTube.
About Arc Institute
Arc Institute is a nonprofit research organization that aims to understand and treat complex human diseases—like cancer, neurodegenerative disorders, and immune conditions—by blending the best of academic freedom and industry-style infrastructure. It supports fully funded, curiosity-driven labs led by faculty at Stanford, UCSF, and UC Berkeley, and builds collaborative Technology Centers focused on genome engineering, multi-omics, computation, and model systems.
Arc's model is built on the belief that technology innovation can catalyze scientific discovery, and its structure emphasizes translational impact by enabling discoveries to move quickly from the lab to the clinic.
